We are delighted to add our latest Educational Series which gives an overview of current practice in the management of Stage 2/3 oesophagogastric cancer focussing on oesophageal cancer (OC) and gastro-oesophageal junction cancer (GOJC) as well as an overview of the Checkmate 577 trial provided as background to the TGA approval of nivolumab as monotherapy for the adjuvant treatment of resected OC or GOJC in patients who have received neoadjuvant chemoradiotherapy.
The review includes guiding commentary from Professor Chris Karapetis, Network Director for Cancer Services in the Southern Area Local Health Network of Adelaide, Head of the Department of Medical Oncology at the Flinders Medical Centre and Director of Clinical Research in Medical Oncology and Dr Matthew Burge, medical oncologist and staff specialist at the Royal Brisbane Hospital and visiting specialist at the Rockhampton Base Hospital.
Please login below to download this issue (PDF)